CPTPP

Comprehensive and Progressive Agreement for Trans-Pacific Partnership

Donald Trump's vow to end TPP affects India’s trade talks
The members common to two agreements (TPP and RCEP), especially developed countries such as Australia, Japan and New Zealand, want talks at the RCEP trade bloc to move ahead full steam
Don’t cry over dead trade agreements
If we can manage our own economies well, new trade pacts will become largely redundant.
The Regional Comprehensive Economic Partnership, intellectual property protection and access to medicines
This paper identifies TRIPS-Plus provisions in leaked RCEP negotiating texts and examines their implications for low and middle-income countries.
RCEP to consolidate Asian integration
The RCEP is part of the efforts of Asian countries to explore avenues of collaborative regional governance. It should be seen as the extension of an integrated ASEAN community
Regional trade meet should not pave way for monopoly in drugs: Doctors without Borders
Doctors Without Borders/Medecins Sans Frontieres (MSF) and other health groups have reiterated concerns about harmful intellectual property provisions in the RCEP
Why did Japan's Parliament ratify 'dead' TPP agreement?
A curious thing happened when the Japanese Parliament voted to ratify Japan's participation in the Trans-Pacific Partnership (TPP) even though the agreement has been widely proclaimed to be "dead"
Diet approves TPP despite Trump’s stated opposition
Although seemingly dead due to opposition from U.S. President-elect Donald Trump, the Trans-Pacific Partnership free trade agreement was approved by the Diet.
China-championed Asia trade pact gains traction in Jakarta talks
Matters such as intellectual property rights, as well as trade in goods and services, remain unresolved. The next talks will be held in Japan in February.
Trade Minister Steven Ciobo rejects assertions that the Trans-Pacific Partnership has collapsed
"We are only nine months into a 24-month process, we need to give the Americans time to consider the pros and cons of the TPP."
TPP may be dead – but its impact lingers
Threats to affordable access to medicines continue unabated